R1 RCM Inc. (NASDAQ:RCM) Given Average Rating of “Buy” by Analysts

Shares of R1 RCM Inc. (NASDAQ:RCMGet Rating) have earned an average rating of “Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $29.25.

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of R1 RCM from $30.00 to $28.00 in a research note on Tuesday. Robert W. Baird raised their price objective on shares of R1 RCM from $29.00 to $32.00 in a research note on Thursday, March 3rd. Zacks Investment Research upgraded shares of R1 RCM from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research note on Thursday, April 21st. Finally, Guggenheim began coverage on shares of R1 RCM in a research note on Wednesday, April 13th. They issued a “neutral” rating for the company.

A number of hedge funds and other institutional investors have recently made changes to their positions in RCM. Eaton Vance Management grew its position in R1 RCM by 81.7% during the third quarter. Eaton Vance Management now owns 3,241,189 shares of the healthcare provider’s stock valued at $71,339,000 after buying an additional 1,457,158 shares during the period. Norges Bank bought a new stake in R1 RCM during the fourth quarter valued at approximately $24,838,000. Invesco Ltd. grew its position in R1 RCM by 189.9% during the fourth quarter. Invesco Ltd. now owns 1,320,553 shares of the healthcare provider’s stock valued at $33,661,000 after buying an additional 865,109 shares during the period. Sunriver Management LLC grew its position in R1 RCM by 58.7% during the third quarter. Sunriver Management LLC now owns 2,319,322 shares of the healthcare provider’s stock valued at $51,048,000 after buying an additional 857,490 shares during the period. Finally, Loomis Sayles & Co. L P grew its position in R1 RCM by 69.8% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,509,665 shares of the healthcare provider’s stock valued at $38,481,000 after buying an additional 620,806 shares during the period. Institutional investors own 41.97% of the company’s stock.

NASDAQ:RCM opened at $19.81 on Wednesday. The firm has a market cap of $5.51 billion, a P/E ratio of -9.21, a P/E/G ratio of 2.46 and a beta of 0.86. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.43 and a current ratio of 1.43. R1 RCM has a fifty-two week low of $18.71 and a fifty-two week high of $27.86. The firm has a 50-day simple moving average of $25.10 and a two-hundred day simple moving average of $24.52.

R1 RCM (NASDAQ:RCMGet Rating) last released its quarterly earnings data on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.04). The firm had revenue of $385.70 million for the quarter, compared to the consensus estimate of $384.18 million. R1 RCM had a net margin of 6.59% and a return on equity of 30.22%. The firm’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.37) earnings per share. On average, equities research analysts predict that R1 RCM will post 0.46 EPS for the current year.

About R1 RCM (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Featured Stories

Analyst Recommendations for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.